Quality & complianceOfficial

Gilead to permanently withdraw Tybost tablets from Danish market from end-December 2026

🇩🇰 DKMA · Wed 28 Oct 2026

The Danish Medicines Agency says Gilead Sciences Sweden AB will stop marketing Tybost (cobicistat) 150 mg tablets for commercial reasons, with the expected period starting at the end of December 2026.

The Danish Medicines Agency (DKMA) has published a supply notice, dated 28 October 2026, saying that marketing of Tybost 150 mg film-coated tablets from Gilead Sciences Sweden AB will cease.

The notice names cobicistat as the active substance and gives the ATC code as V03AX03. It gives the expected period as from the end of December 2026 and the reason as commercial. DKMA describes the move as a permanent market withdrawal, not a temporary interruption.

Cobicistat is a pharmacokinetic booster used within HIV treatment regimens. The notice itself does not discuss clinical consequences or name alternative products. It says questions about the current status should be put to the company.

The entry appears in DKMA's section for supply notices on medicines. It is filed there as a supply difficulty, although the underlying decision is a permanent cessation of marketing.

What it means for your team

  • Supply and market-access teams should confirm with Gilead the exact last-supply date and any remaining stock in Denmark, since the notice gives only 'from end December 2026'.
  • Pharmacovigilance and medical teams should check whether patients or regimens in Denmark rely on this presentation and plan for any switch with prescribers.
  • Quality and regulatory teams should note that this is a permanent cessation for commercial reasons, not a shortage with an expected return.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →